The Reality of Enrollment Expectations
SOCRA's 2019 Annual Conference
Harvey Arbit, PharmD, MBA, CCRP, RAC, President, Arbit Consulting, LLC
Louis Lasagna was the founder of the Tufts Center for the Study of Drug Development at Tufts University where he became Dean of the Sackler School of Graduate Biomedical Sciences. Lasagna’s Law states “The incidence of patient availability sharply decreases when a clinical trial begins and returns to its original level as soon as the trial is completed.” Why is this true? Can it ever be changed? If not, why not?